MEM.PD119/MEM.PD205/MEM.PD361 / GB Sciences - LARVOL DELTA

Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge (Yahoo News) - "Gb Sciences, Inc...has selected the University of Lethbridge in Canada to complete a dose range study of Gb Sciences' patent-protected formulations in a rodent model of Parkinson's disease (PD). Gb Sciences plans on filing an Investigational New Drug Application to begin first-in-human clinical trials as early as next year....Through GbS Global Biopharma, its wholly owned Canadian subsidiary, Gb Sciences has signed a contract with the University of Lethbridge, located in Alberta, Canada, to complete required rodent dose response studies. These important studies will determine the dose range of active ingredients that will be used in human trials and will identify potential side effects. These dose range studies are scheduled to begin next month."

IND • Licensing / partnership • Preclinical • CNS Disorders • Parkinson's Disease